Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Permalink
https://escholarship.org/uc/item/3xf925hz

Journal
Gynecologic Oncology, 143(3)

ISSN
0090-8258

Authors
Fader, Amanda N
Java, James
Tenney, Meaghan
et al.

Publication Date
2016-12-01

DOI
10.1016/j.ygyno.2016.10.016

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Amanda N. Fader, MD,⁎, James Java, PhD,⁎⁎, Meaghan Tenney, MD,⁎, Stephanie Ricci, MD,⁎,⁎¹, Camille C. Gunderson, MD,⁎️, Sarah M. Temkin, MD,⁎,⁎️, Nick Spirtos, MD,⁎,⁎️, Christina L. Kushnir, MD,⁎,⁎️, Michael L. Pearl, MD,⁎,⁎️, Oliver Zivanovic, MD,⁎,⁎️, Krishnansu S. Tewari, MD,⁎️, David O’Malley, MD,⁎,⁎️, Ellen M. Hartenbach, MD,⁎,⁎️, Chad A. Hamilton, MD,⁎,⁎️, Natalie S. Gould, MD,⁎,⁎️, Robert S. Mannel, MD,⁎,⁎️, William Rodgers, MD,⁎,⁎️, Joan L. Walker, MD,⁎,⁎️

Objective. We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial.

Methods. This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

HIGHLIGHTS

• Women with early-stage uterine serous and carcinosarcoma have poor survival.
• Recurrence patterns were similar in those staged with laparoscopy vs laparotomy.
• Survival is similar for high-grade uterine cancer patients staged via laparoscopy.

ARTICLE INFO

Article history:
Received 25 August 2016
Received in revised form 8 October 2016
Accepted 9 October 2016
Available online 12 October 2016

ABSTRACT

Objectives. We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial.

Methods. This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.

⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.

⁎⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.

⁎⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.

⁎⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.

⁎⁎ These findings were presented at the Society of Gynecologic Oncology’s 43rd Annual Meeting on Women’s Cancer in Tampa, Florida, March 22–25, 2014. This study was supported by National Cancer Institute grants to the University of Oklahoma (1CA65221), the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868). The following Gynecologic Oncology Group (GOG) institutions participated in the GOG 2222 (LAP2) study: Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, University of California at San Diego, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St Luke’s Medical Center, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Women’s Cancer Center, University of Oklahoma, Tacoa General Hospital, Tampa Bay Cancer Consortium, Gynecologic Oncology Network, Fletcher Allen Health Care, University of Wisconsin Hospital, Women and Infants Hospital, and Community Clinical Oncology Program.
Keywords:
LAP-2 trial
Uterine cancer
High-grade uterine cancer
Type II uterine cancer
Minimally invasive surgery

1. Introduction

Uterine cancer is not a single disease, but consists of several histologic subtypes, with different risk factors, precursor lesions, molecular and genetic profiles, and clinical outcomes. Epithelial uterine cancer has been historically classified into two subtypes, Type I and Type II, based on histologic and molecular characteristics [1,2]. Observations by Lauchlan, Hendrickson, and Bohman led to the description of these two distinct types, with Type I, commonly referred to as the endometrioid type, comprising 80–90% of all uterine cancers, and Type II, most often non-endometrioid tumors, encompassing the remaining 10–20% of endometrial tumors [3–5]. The most common histologies of this latter subtype include uterine serous carcinoma (USC) and clear-cell carcinoma (CCC). Additionally, carcinosarcoma (CS), a biphagic, high-grade epithelial uterine tumor, behaves similarly to the Type II tumors and is often classified as such [6].

In general, Type II uterine neoplasms are associated with more aggressive tumor biology and clinical behavior than Type I tumors, accounting for more than 40% of all uterine cancer deaths. However, this has not been observed in all studies [3–5,7–8]. At least one study from the Gynecologic Oncology Group (GOG) suggested the association between tumor type and prognosis was weak for patients with advanced/recurrent uterine cancer [9]. Additionally, although it is often labeled as a Type II cancer, grade 3 endometrioid adenocarcinoma is an entity that may defy categorization, despite its endometrioid histotype. Some studies demonstrate that USC and CCC are associated with an unfavorable prognosis compared with grade 3 endometrioid cancer, while a recent clinicopathologic analysis revealed no difference in outcome between these histologies [7–8,10].

Survival outcomes for the GOG LAP-2 study, a multicenter phase III study of women with apparent early-stage, grade 1–3 uterine cancer randomized to laparoscopy versus laparotomy, have been previously reported [11]. While the authors suggest that histologic cell type should not necessarily be a factor in the decision to offer minimally invasive surgery, detailed data regarding the women with high-grade disease from the LAP-2 cohort remains unexplored. There are few large prospective studies describing the impact of high-risk uterine cancer histologies on patient prognosis. There are even fewer published reports evaluating the role of minimally invasive surgery in the management of high-grade uterine malignancies [12]. Therefore, the primary study aim was to examine the clinicopathologic features and prognostic differences among histologic cell types in women with high-grade uterine cancer enrolled in a cooperative group trial. A secondary aim was to compare the oncologic outcomes of this same population staged by minimally invasive approaches versus laparotomy.

2. Methods

This was an institutional review board exempt study. An ancillary analysis of the GOG LAP-2 trial, a multicenter phase III study of women with apparent early-stage uterine cancer randomized 2:1 to laparoscopy versus laparotomy, was performed. Data was collected on women with high-grade malignancies; specifically, grade 3 endometrioid, and those with Type II uterine cancers, including USC, CCC and carcinosarcoma. Representative slides from the hysterectomy specimens were submitted for central review and were performed by two members of the GOG Pathology Committee. Specimens containing >10% serous adenocarcinoma were designated as uterine serous carcinoma. Standardized pathology evaluation forms were to be completed prospectively by the local GOG pathologist, documenting the number of nodes removed and the number of positive nodes at each of four regions (right pelvic, left pelvic, right para-aortic, and left para-aortic). FIGO staging and prognostic criteria (depth of myometrial invasion, cervical involvement, lymphovascular invasion, metastatic sites, and peritoneal cytology results) were also collected prospectively, along with copies of pathology and cytology reports. We conducted an analysis comparing the grade 3 endometrioid tumors to the other three tumor histologies combined (collectively known as “other” Type II cancers) and an additional subset analysis stratified by individual histology. Demographics, clinicopathologic features, rates and patterns of recurrence, adjuvant treatment, progression-free survival (PFS) and overall survival (OS) were compared by histology and surgical staging approach (laparoscopy versus laparotomy).

Categorical variables were compared between the patient subgroups by the Pearson chi-square test [13], and continuous variables by the Wilcoxon–Mann–Whitney test [14] or the Kruskal–Wallis test [15]. Survival was estimated using the Kaplan–Meier [16] method. The Cox proportional hazards model [17] was used to evaluate independent prognostic factors identified by previous GOG studies, and to estimate their covariate-adjusted effects on survival. All statistical tests were two-tailed with the significance level set at a = 0.05, except where noted. Statistical analyses were performed using the R programming language and environment [18].

3. Results

Of 2600 patients enrolled in the LAP-2 trial, we identified 753 patients with high-grade disease: 350 were diagnosed with endometrioid; 289 with USC; 72 with carcinosarcoma; and 42 with CCC. Laparoscopy was performed in 507 patients and laparotomy in 246. Demographic and clinicopathologic data stratified by uterine tumor histology is shown in Table 1. Compared with the grade 3 endometrioid cohort, those with “other” Type II uterine cancers were more likely: older (median age 69.4 vs 61.8, respectively; p < 0.001); to have positive peritoneal cytology (20.2% vs 7.7%, respectively; p < 0.001); to have positive lymph nodes (22.6% vs 16.9%, respectively; p = 0.05); to have higher disease stage on final pathology (p < 0.001) and to undergo a conversion to laparotomy due to metastatic disease (34.3% vs. 23.3%; p = 0.008). With a median follow-up time of 60 months, patients with “other” Type II uterine cancers had almost double the recurrence rates (26.6% vs 13.7%; p < 0.001), were more likely to have a multisite or extra-pelvic recurrence (p < 0.001) and had poorer median PFS (59.3% vs 77.4%).
p < 0.001) and median OS (65.5% vs 81.7%; p < 0.001) than the grade 3 endometrioid cohort (Fig. 1). This was despite the fact that the grade 3 endometrioid cohort received significantly less adjuvant therapy overall than those with other Type II malignancies (Table 2; p < 0.001). Specifically, patients with grade 3 endometrioid disease were more likely to undergo observation after surgery (no therapy: 52.5% vs 41.7%, respectively; p < 0.001), less likely to receive chemotherapy (4.2% vs 18.8%, respectively; p < 0.001) or combination chemotherapy and radiation (8.4% vs 19.1%, respectively; p < 0.001), although more received radiation alone than the other Type II cohort (34.9% vs 20.4%, respectively; p < 0.001).

When examining outcomes of the patients with high-grade histologies by surgical approach (Table 3), there were no differences in age, race, body mass index, performance status, number or type of lymph nodes removed, number of positive lymph nodes, stage or adjuvant therapies between the laparoscopy and laparotomy cohorts. Recurrence rates (25.5% versus 27.9%, respectively), patterns of recurrence, PFS, and OS (Fig. 2) were also not significantly different in those staged with laparoscopy vs laparotomy (Table 3). Further, the incidence of trocar-site metastesas was only 0.2% in the laparoscopy cohort.

Survival stratified by histology is shown in Figs. 1a and 1b. Compared to those with grade 3 endometrioid, those with CCC experienced similar PFS and OS outcomes, while women with USC (PFS HR: 1.36; OS HR: 1.26) and carcinosarcoma (PFS HR: 2.12 and OS HR: 2.33) had poorer PFS (p < 0.004) and OS rates (p < 0.003), respectively. Those with carcinosarcoma experienced the worst survival outcomes. On multivariable analysis, age (PFS HR: 1.038, 95% CI 1.023–1.054, p = 0.001; OS HR: 1.052, 95% CI 1.035–1.070, p < 0.001), pelvic washings (PFS HR: 1.801, 95% CI: 1.248–2.598, p = 0.004; OS HR: 1.898, 95% CI: 1.274–2.287, p = 0.004); advanced stage (ref: stage IA; PFS stage IIIIC1 HR: 2.854, 95% CI: 1.748–4.660, p < 0.001; OS stage IIIIC1 HR: 2.692, 95% CI: 1.561–4.618, p < 0.001; PFS stage IIIC2 HR: 4.284, 95% CI: 2.640–6.592, p < 0.001; OS stage IIIC2 HR: 4.310, 95% CI: 2.549–7.286, p < 0.001; PFS Stage IVB HR 11.976, 95% CI 6.890–20.818, p < 0.001; OS Stage IVB HR: 11.533, 95% CI 6.518–20.408, p < 0.001) and other Type II histologies (ref: grade 3 endometrioid; PFS HR: 1.483, 95% CI 1.086–2.026; p = 0.005; OS HR: 1.506, 95% CI 1.058–2.124; p = 0.014) were independently and adversely associated with both PFS and OS (Tables 4a and 4b, respectively). Choice of adjuvant therapy and surgical approach (Fig. 2) were not associated with survival outcomes.

4. Discussion

While most uterine corpus cancers are early-stage, low-grade Type I tumors with an excellent prognosis, grade 3 endometrioid adenocarcinoma, USC, CCC and carcinosarcoma have been identified as distinct, high-risk variants, each with a poorer prognosis than the Type I cancers [8,11]. Although these high-grade subtypes account for fewer than 25% of all uterine cancers, they collectively account for more than 50% of uterine cancer deaths [12,19]. Thus, it is paramount that cancer centers and cooperative trial groups focus greater attention on development of preventive oncology measures and innovative therapeutic strategies concentrated on these tumor types. Previous studies have shown that women with grade 3 endometrioid disease have better survival outcomes [20], other authors have not demonstrated a survival difference between this subtype and serous and clear cell histologies [19,21]. However, these reports are mostly small, retrospective series that lack power to detect significant differences among rare tumor histologies. The findings of one of the larger retrospective studies of the Surveillance, Epidemiology and End Results (SEER) database analysis [22] showed that five-year survival rates for USC and CCC were 72% and 80%, respectively, whereas the corresponding survival rate for grade 3 endometrioid cancers was 89% (p < 0.0001). Our ad hoc study of a Phase III GOG trial in 753 patients with surgically staged, high-grade uterine cancer adds to this literature. Compared to the grade 3 endometrioid adenocarcinoma cohort, those with apparent early-stage “other” Type II cancers were older and were more likely to have positive lymph nodes and higher disease stage on final pathology. It was not surprising that with more advanced disease evident at surgical staging, patients diagnosed with “other” Type II histologies had higher recurrence rates and poorer PFS and OS than the grade 3 endometrioid cohort. However, after controlling for age, stage, adjuvant treatment and other factors on multivariable analysis, “other” Type II histologies remained an independent factor adversely associated with survival (Tables 4a and 4b), with the poorer survival outcomes in this cohort largely attributed to the serous and carcinosarcoma histologies (Figs. 1a and 1b).

While the NRG/GOG has recently defined carcinosarcoma as a separate entity in terms of clinical trials development [23], with rare exception [24], women with uterine serous and clear cell histologies continue to be grouped together in most clinical trials with those who have grade 1–3 endometrioid cancers [25–29]. Questions remain, most importantly, does a significant difference in prognosis exist among these high-risk histologies, do the various high-risk tumors respond differently to adjuvant treatment, and ultimately, should these cell types be treated as separate disease entities? In a recent large GOG study exploring the etiologic heterogeneity of uterine cancer, those with Type II cancers were...
older, more often non-white and less often obese compared to women grade 1–2 endometrioid cancers [10]. Risk factors for grade 3 endometrioid carcinomas were generally similar to those identified for Type II cancers, although patients with grade 3 endometrioid tumors more often had histories of breast cancer without tamoxifen exposure while those with other Type II tumors, including carcinosarcoma and serous histologies, were more frequently treated with tamoxifen. These findings underscore the clinical and molecular distinctions between the low and high-risk subtypes as well as more nuanced etiologic differences among the high-risk histologies.

Table 2
Recurrence and survival by histology.

|                | Endometrioid | Other       | Test statistic |
|----------------|--------------|-------------|----------------|
| N              | N = 350      | N = 403     |                |
| Adjuvant therapy |              |             |                |
| None           | 52.5% (176)  | 41.7% (164) | p < 0.001      |
| Chemotherapy   | 4.2% (14)    | 18.8% (74)  |                |
| Radiation      | 34.9% (117)  | 20.4% (80)  |                |
| Both           | 8.4% (28)    | 19.1% (75)  |                |
| Recurrence     | 753          | p < 0.001   |                |
| No             | 86.3% (302)  | 73.4% (296) |                |
| Yes            | 13.7% (48)   | 26.6% (107) |                |
| Site of recurrence |          |             | p < 0.001      |
| Trocar         | 0.3% (1)     | 0.2% (1)    |                |
| Vagina         | 2.0% (7)     | 3.0% (12)   |                |
| Pelvis         | 1.4% (5)     | 4.0% (16)   |                |
| Abdomen        | 1.4% (5)     | 5.3% (22)   |                |
| Liver          | 0.3% (1)     | 2.5% (10)   |                |
| Lung           | 2.6% (9)     | 4.2% (17)   |                |
| Bone           | 0.0% (0)     | 0.5% (2)    |                |
| Nodal          | 2.6% (9)     | 2.0% (8)    |                |
| Multiple       | 2.0% (7)     | 4.5% (18)   |                |
| Unknown        | 1.1% (4)     | 0.2% (1)    |                |
| No recurrence  | 86.3% (302)  | 73.4% (296) |                |
| Progression-free survival status | 753 | p < 0.001 |
| Censored       | 77.4% (271)  | 59.3% (239) |                |
| Progression or death | 22.6% (79)  | 40.7% (164) |                |
| Overall survival status | 753 | p < 0.001 |
| Censored       | 81.7% (286)  | 65.5% (264) |                |
| Death          | 18.3% (64)   | 34.5% (139) |                |
| Cause of death | 203          | p = 0.213   |                |
| Disease        | 60.9% (39)   | 69.8% (97)  |                |
| Other          | 39.1% (25)   | 30.2% (42)  |                |

N is the number of non-missing values. Numbers after percents are frequencies.
Test used: Pearson test

Table 3
Patterns and Rates of Recurrence and Survival by Laparoscopy vs. Laparotomy.

|                | Laparoscopy | Laparotomy | Test statistic |
|----------------|-------------|------------|----------------|
| N              | N = 274     | N = 129    |                |
| Adjuvant therapy |            |            | p = 0.533      |
| None           | 40.2% (107) | 44.9% (57) |                |
| Chemotherapy   | 18.4% (49)  | 19.7% (25) |                |
| Radiation      | 20.3% (54)  | 20.5% (26) |                |
| Both           | 21.1% (56)  | 15.0% (19) |                |
| Recurrence     | 403         | p = 0.672  |                |
| No             | 74.1% (203) | 72.1% (93) |                |
| Yes            | 25.9% (71)  | 27.9% (36) |                |
| Site of recurrence |        |            | p = 0.882      |
| Trocar         | 0.4% (1)    | 0.0% (0)   |                |
| Vagina         | 2.2% (6)    | 4.7% (6)   |                |
| Pelvis         | 4.7% (13)   | 2.3% (3)   |                |
| Abdomen        | 5.1% (14)   | 6.2% (8)   |                |
| Liver          | 2.6% (7)    | 2.3% (3)   |                |
| Lung           | 4.4% (12)   | 3.9% (5)   |                |
| Bone           | 0.4% (1)    | 0.8% (1)   |                |
| Nodal          | 1.8% (5)    | 2.3% (3)   |                |
| Multiple       | 4.0% (11)   | 5.4% (7)   |                |
| Unknown        | 0.6% (1)    | 0.0% (0)   |                |
| No recurrence  | 74.1% (203) | 72.1% (93) |                |
| Progression-free survival status | 403 | p = 0.745 |
| Censored       | 58.8% (161) | 60.5% (78) |                |
| Progression or death | 41.2% (113) | 39.5% (51) |                |
| Overall survival status | 403 | p = 0.737 |
| Censored       | 65.0% (178) | 66.7% (86) |                |
| Death          | 35.0% (96)  | 33.3% (43) |                |
| Cause of death | 139         | p = 0.687  |                |
| Disease        | 70.8% (68)  | 67.4% (29) |                |
| Other          | 29.2% (28)  | 32.6% (14) |                |

N is the number of non-missing values. Numbers after percents are frequencies.
Test used: Pearson test
While some Phase III studies of advanced or recurrent uterine cancer have not demonstrated a difference in survival outcomes based upon grade or histology [9], no trial has been powered to evaluate the impact of Type II uterine histologies on outcome. Nevertheless, subgroup analysis of two GOG Phase III studies of women with advanced or recurrent uterine cancer, a clear difference in prognosis was observed based on histology and grade [26,27]. Randall et al. compared whole abdominal radiation to chemotherapy in women with advanced or recurrent endometrial cancer [26]. An exploratory multivariate analysis demonstrated that grade 3 tumors and serous histology were adversely associated with survival. A subsequent Phase III GOG study in the same population studying cisplatin, doxorubicin and whole pelvic radiation randomized with and without paclitaxel demonstrated poorer outcomes based on histology [27]. Unadjusted Kaplan-Meier estimates of recurrence-free survival by histology and grade demonstrated lower survival for patients with advanced or recurrent clear cell and serous histologies compared with endometrioid types [27]. Additionally, relative to those with grade 1 endometrioid adenocarcinoma, patients with grade 3 endometrioid disease had a recurrence-free survival hazard ratio of 3.12, which was similar to that of 3.45 for clear cell histology. However, serous histology had the most adverse survival impact, with a hazard ratio of 4.43. In the current ad hoc analysis, almost double the recurrence rate, a propensity for extra-pelvic recurrence, and a greater risk of cancer-specific mortality was observed in the “other” Type II cohort compared to the grade 3 endometrioid carcinoma cohort. These recent GOG/NRG studies in women with both early and advanced-stage uterine cancer demonstrate clear differences in treatment response as well as strong etiologic and prognostic distinctions in those with endometrioid carcinoma compared with women diagnosed with more high-risk histologies, providing compelling clinical evidence to support the development of distinct clinical trials for women with Type II histologies.

Recently, a comprehensive genomic analysis of nearly 400 endometrial tumors suggested that certain molecular characteristics, including mutation frequency, may complement current pathology methods and help distinguish between primary uterine tumor types, as well as provide insights into potential treatment approaches [28]. The study, led by investigators in The Cancer Genome Atlas Research Network, identified genomic similarities between endometrial and other cancers, including breast, ovarian, and colorectal cancers, and revealed four novel tumoral molecular uterine subtypes. These molecular classifications may help better stratify patients for enrollment in clinical trials with targeted therapies. Given the substantial differences in genetic and molecular profiles between the “Type II” uterine tumors, should the dichotomous Type I and II classification be abandoned? This is not an academic concern, occurring in 1% of patients historically classified as Type II. The clinical utility of this classification is likely to be realized in the near future.

Finally, the GOG LAP-2 protocol randomized over 2600 women with endometrial cancer to laparotomy versus laparoscopy and reported fewer postoperative moderate or severe adverse events, shorter hospital stays, less pain, earlier resumption of normal activities and improved short-term quality of life in the laparoscopy cohort [11]. The estimated 5-year OS was nearly identical between the cohorts at 89.8%. However, this and other randomized studies of minimally invasive surgery in uterine cancer were focused on patients with relatively low-risk, grade 1–2 endometrial tumors. Our current ad hoc LAP-2 analysis demonstrates that survival is not compromised for patients with high-grade uterine cancers staged via laparoscopy, which corresponds with a retrospective, multi-institutional study performed at high-volume U.S. cancer centers demonstrating similar results [12]. Further, trocar site recurrences were not a significant concern, occurring in < 1% of patients treated with laparoscopy. Recognizing that women diagnosed with Type II, high-grade uterine cancer are usually older, possess comorbidities and are more likely to require adjuvant therapies than those with Type I malignancies, there is great interest in minimizing surgical

Table 4a
Multivariate progression-free survival analysis.

|                        | HR  | 2.5% | 97.5% | p    |
|------------------------|-----|------|-------|------|
| Histology (endometrioid ref.) other | 1.483 | 1.086 | 2.026 | 0.013 |
| Age                    | 1.038 | 1.023 | 1.054 | <0.001 |
| Race (White ref.) Hispanic | 2.281 | 1.144 | 4.549 | 0.019 |
| Black                  | 1.202 | 0.647 | 2.236 | 0.360 |
| Other                  | 1.252 | 0.672 | 2.330 | 0.479 |
| Performance status (0 ref.) 1, 2, 3 | 1.467 | 0.977 | 2.205 | 0.065 |
| Positive washings (no ref.) yes | 1.801 | 1.248 | 2.598 | 0.002 |
| Stage (IA ref.) IB      | 1.585 | 1.015 | 2.474 | 0.043 |
| II                     | 2.376 | 1.256 | 4.495 | 0.008 |
| IIIA                   | 1.522 | 0.711 | 2.577 | 0.279 |
| IIIC1                  | 2.854 | 1.748 | 4.660 | <0.001 |
| IIIC2                  | 4.284 | 2.640 | 6.952 | <0.001 |
| IVB                    | 11.976 | 6.890 | 20.818 | <0.001 |
| Adjuvant treatment (observation ref.) chemotherapy | 0.587 | 0.353 | 0.976 | 0.040 |
| Radiation              | 0.841 | 0.577 | 1.224 | 0.366 |
| Both                   | 0.956 | 0.605 | 1.510 | 0.846 |

Table 4b
Multivariate overall survival analysis.

|                        | HR  | 2.5% | 97.5% | p    |
|------------------------|-----|------|-------|------|
| Histology (endometrioid ref.) other | 1.506 | 1.058 | 2.144 | 0.023 |
| Age                    | 1.052 | 1.035 | 1.070 | <0.001 |
| Race (White ref.) Hispanic | 2.702 | 1.297 | 5.629 | 0.008 |
| Black                  | 1.210 | 0.610 | 2.402 | 0.585 |
| Other                  | 1.342 | 0.672 | 2.679 | 0.405 |
| Performance status (0 ref.) 1, 2, 3 | 1.463 | 0.937 | 2.284 | 0.094 |
| Positive washings (no ref.) yes | 1.898 | 1.274 | 2.827 | 0.002 |
| Stage (IA ref.) IB      | 1.262 | 0.752 | 2.116 | 0.379 |
| II                     | 1.672 | 0.784 | 3.566 | 0.183 |
| IIIA                   | 1.437 | 0.600 | 3.441 | 0.416 |
| IIIC1                  | 2.902 | 1.569 | 4.618 | <0.001 |
| IIIC2                  | 4.310 | 2.549 | 7.286 | <0.001 |
| IVB                    | 11.533 | 6.518 | 20.408 | <0.001 |
| Adjuvant treatment (observation ref.) chemotherapy | 0.481 | 0.272 | 0.850 | 0.012 |
| Radiation              | 0.975 | 0.642 | 1.482 | 0.907 |
| Both                   | 1.091 | 0.662 | 1.799 | 0.733 |
morbidity in this population [12]. While more patients with Type II disease are found to have extra-uterine disease at primary surgery and should be counseled that conversion rates to laparotomy might be higher in this population, minimally invasive surgery should be the preferred surgical modality in this high-risk patient cohort in the absence of obvious extra-uterine disease or other contraindications to laparoscopy.

An additional surgical observation in our study was that positive peritoneal cytology (i.e., washings) correlated strongly and adversely with PFS and OS on multivariate analysis. While positive peritoneal cytology in early-stage uterine cancer does not appear to influence prognosis in those with low-grade disease (and for this reason, was removed from the 2009 FIGO staging criteria) [29], it is more likely that in those with high-risk histologies, positive washings are not a random event and are more prognostic of outcome. Consideration should be given to performance of peritoneal cytology in all women with a preoperative diagnosis of high-grade uterine cancer, as the information gained from this procedure may influence decision-making regarding adjuvant therapies.

Study weaknesses include the ad hoc analysis with its intrinsic limitations and that study participants received a heterogeneous array of adjuvant therapies. Study strengths include the prospectively collected data from a phase III GOG study, the large sample size of study subjects with high-grade uterine cancer and that tumor specimens had undergone central pathology review by GOG pathologists.

In conclusion, women with apparent early-stage, Type II uterine cancer—especially those with serous and carcinosarcoma histologies—are older, more likely to have advanced-stage disease on final pathology, higher recurrence rates and poorer survival outcomes than women with grade 3 endometrioid adenocarcinoma. Despite the biological aggressiveness of these high-risk histologies, women with high-grade uterine cancer staged via laparoscopy had similar patterns of recurrence and survival as those staged by laparotomy. Given the significant molecular and prognostic differences among these histologic cell types, future cooperative group initiatives should focus on development of distinct treatment trials for patients with Type II malignancies that include histologic and genomic tumor classifications so that outcomes for women with rare, but deadly, uterine malignancies can be improved.

Conflicts of interest
Dr. Nick Spirtos receives per capita reimbursement to the Women’s Cancer Center, travel supplement as Gyn Onc Committee Chair, co-operative research funding on a per capita basis from GOG Foundation, Inc., and royalties from Wiley Health Services for Bonney’s Gynaecological Surgery.

Dr. Michael Pearl receives grant money from the GOG/NRG. He also serves as a consultant for Ethicon, provided expert testimony for legal expert review, and has grants/grants pending from NIH, small foundations, as well as royalties from VitaTex.

Dr. David O’Malley serves as a consultant for Yondelis on the Sarcoma Advisory Board, AstraZeneca on the Ovarian Cancer Advisory Board, Clovis on the Ovarian Cancer Advisory Board, Genentech/Roche on the Ovarian Cancer Advisory Board and Eisai on the Advisory Board.

Dr. Robert Mannel receives grant monies from GOG-LAP2 grant. He also serves on the Advisory Board as a consultant for Medimmune, Oxigene, Endocyte, Bayer and Clovis.

All other coauthors have no conflicts of interest to declare.

References
[1] A.S. Felix, J.L. Weissfeld, R.A. Stone, R. Bower, M. Chivukula, R.P. Edwards, et al., Factors associated with type I and type II endometrial cancer, Cancer Causes Control 21 (2010) 1851–1856.
[2] M.E. Sherman, Theories of endometrial carcinogenesis: a multidisciplinary approach, Mod. Pathol. 13 (2000) 295–308.
[3] J.V. Boltman, Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol. 15 (1983) 10–17.
[4] J.L. Hecht, G.L. Mutter, Molecular and pathologic aspects of endometrial carcinogenesis, J. Clin. Oncol. 24 (2006) 4783–4791.
[5] K.N. Moore, A.N. Fader, Uterine papillary serous carcinoma, Clin. Obstet. Gynecol. 54 (2011) 278–291.
[6] D. Beutner-Rigaud, M. Devousaux-Shibeshoan, J.A. Ledermann, M.M. Leitao, P. Ma, A. Poveda, et al., Gynecologic Cancer Inter-Group (GCIG): consensus review for uterine and ovarian carcinoma, Int. J. Gynecol. Cancer 24 (9 Suppl 3) (2014 Nov) 550–560.
[7] J. Prat, A. Gallardo, M. Cuatresacs, L. Catasús, Endometrial carcinoma: pathology and genetics, Pathology 39 (2007) 72–87.
[8] H.J. Kim, T.J. Kim, Y.Y. Lee, C.H. Choi, J.W. Lee, D.S. Bae, B.G. Kim, A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometroid corpus cancers using 2009 FIGO staging system, J. Gynecol. Oncol. 24 (2) (2013) 120–127.
[9] D.S. McMeekin, V. Filicoci, J.T. Thigpen, H.H. Gallion, G.F. Fleming, H.W. Rodgers, et al., The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first line chemotherapy trials: a Gynecologic Oncology Group Study, Gynecol. Oncol. 106 (6 Suppl 1) (2007 July) 16–22.
[10] L.A. Brinton, A.S. Felix, D.S. McMeekin, W.T. Creasman, M.E. Sherman, D. Mutch, et al., Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial, Gynecol. Oncol. 129 (4) (2013 May) 277–284, http://dx.doi.org/10.1016/j.ygyno.2013.02.023 (Epub 2013 Feb 26).
[11] J.L. Walker, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, R.S. Mannel, et al., Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Lapar Study, J. Clin. Oncol. 30 (2012) 695–700.
[12] A.N. Fader, L.G. Seamon, P.F. Escobar, H.E. Frasure, L.A. Havrilesky, K.M. Zanotti, et al., Minimally Invasive Surgery versus laparotomy in women with high-grade endometrial cancer: a multi-institutional study at high volume centers, Gynecol. Oncol. 126 (2012) 180–185.
[13] K. Pearson, On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling, Philos. Mag. 50 (1910) 1617–177.
[14] H.B. Mann, D.R. Whitney. On a test of whether one of two random variables is stochastically larger than the other, Ann. Math. Stat. 18 (1947) 50–60.
[15] W.H. Kruskal, W.A. Wallis, Use of ranks in one-criterion variance analysis, J. Am. Stat. Assoc. 47 (1952) 582–612.
[16] E.L. Kaplan, P. Meier, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc. 53 (1958) 457–481.
[17] D.R. Cox, Regression models and life-tables, J. R. Stat. Soc. Ser. B Methodol. 34 (1972) 187–220.
[18] R Core Team: R, A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2014 (URL http://www.R-project.org/).
[19] P.B. Clement, R.H. Young, Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects, Adv. Anat. Pathol. 11 (2004) 117–142.
[20] W.T. Creasman, M.E. Kohler, F. D’Icino, P. Maisonneuve, P. Boyle, Prognosis of papillary serous carcinoma, clear cell, and grade 3 stage I endometrial carcinoma, Gynecol. Oncol. 95 (2004) 593–596.
[21] K.M. Aekitis, A. McKeer, O. Lin, E. Venkataratnam, M.J. Zelefsky, B. Mckee. Is there a difference in outcome between stage I-II endometrial cancer of papillary versus clear cell and endometrioid FIGO stage 3? Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 79–85.
[22] C. Hamilton, M.S. Creugn, K. Osamu, L. Chen, J.K. Chan, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometroid corpus cancers, Br. J. Cancer 94 (2006) 642–646.
[23] https://clinicaltrials.gov/ct2/show/NCT00954174.
[24] H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaine, N.M. Spirtos, J.D. Blass, et al., A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group Study, Gynecol. Oncol. 92 (2004) 744–751.
[25] G.F. Fleming, V.L. Brunetto, D. Celli, K.Y. Look, G.C. Reid, A.R. Munkarah, et al., Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus ifosfamide in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study, J. Clin. Oncol. 22 (2004) 2159–2166.
[26] H.D. Horneley, V. Filicoci, S.K. Gibbons, H.J. Long, D. Cella, N.M. Spirtos, et al., A randomized phase III trial of advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin in a randomized phase II adjuvant chemotherapy trial: a Gynecologic Oncology Group Study, J. Clin. Oncol. 24 (2006) 36–44.
[27] D.A. Kohn, J. Curry, F. Itri, P. Maitland, L. Kattan, et al., The survival and prognostic significance of the use of laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study, J. Clin. Oncol. 24 (2) (2006) 2159–2166.